Total Return chart Genexine, Inc.

Stocks

End-of-day quote Korea S.E. 2026-08-14			5-day change	1st Jan Change
2,620.00 ^KRW	-0.19%		-2.42%	-44.08%

04-28	Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models	CI
03-16	Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101)	CI

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.